New hope for kids with Drug-Resistant TB: delamanid studied in children

NCT ID NCT03141060

Completed Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug delamanid in 37 children with multidrug-resistant tuberculosis (MDR-TB), some of whom also had HIV. The goal was to see how the drug works in the body, check for side effects, and find the right dose. Children took delamanid along with their regular TB medicines for 24 weeks. The results help doctors understand how to safely use this treatment in younger patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: delamanid
What this could lead to: If successful, this could help establish safe and effective dosing of delamanid for children with drug-resistant TB, improving treatment options for this hard-to-treat infection.
What could go wrong: This was a small, early-phase study (37 children) focused on safety and drug levels, not on cure rates. Side effects like heart rhythm changes or severe adverse events are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease multidrug-resistant tuberculosis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS TUBERCULOSIS

Contacts and locations

Locations

Byramjee Jeejeebhoy Medical College (BJMC) CRS

Pune, Maharashtra, 411001, India
Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS

Cape Town, Western Cape, 7505, South Africa
Kilimanjaro Christian Medical Centre (KCMC)

Moshi, Tanzania
PHRU Matlosana CRS

Klerksdorp, North West, 2574, South Africa
Sizwe CRS

Johannesburg, Gauteng, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.